Answers are grounded in this paper and cite their sources.
A pilot study assessed the acceptability of an information leaflet about compounded melatonin, indicating its importance for parents and carers.
Background: Manufactured melatonin liquid is not available as a proprietary product in Australia, and when prescribed for children, is supplied as a compounded product. It may be challenging for a parent/carer to find reliable product information on compounded medicines, as there is no available standardised information or leaflet. Aim: The aim was to develop an information leaflet on extemporaneously prepared melatonin liquid for parents and carers, and to evaluate its readability and acceptability. Method: A leaflet was designed following guidelines for written information. For evaluation of the leaflet, a questionnaire was developed in consultation with a statistician and a pharmacy academic, and was piloted for face validity. The questionnaire elicited feedback about the leaflet design and content, and collected key participant demographics. The prototype leaflet and questionnaires were distributed to a convenience sample of five pharmacies in New South Wales. Results: All participants (i.e. parents/carers) (n=16) felt that it was important to receive written information for melatonin liquid, and found the leaflet easy to understand. Most (94%; n=15) felt that they learnt something new after reading the leaflet, although three (19%; n=3) had unanswered questions, and nearly one-third (31%; n=5) felt somewhat concerned after reading the adverse reactions section of the leaflet. Conclusion: The leaflet about compounded melatonin liquid was deemed acceptable by parents/carers.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: